BET-IN-14 is an orally active pan BET inhibitor (IC50: 5.35 nM). BET-IN-14 has anti-cancer activity[1].
in vivo
BET-IN-14 (Compound 171) (50 and 100 mg/kg, p.o., qd) inhibits tumor growth in MV-4-11 xenograft[1].
Animal Model:
Human MV-4-11 xenografts in Balb/c nude mice[1]
Dosage:
50 and 100 mg/kg
Administration:
p.o., qd
Result:
Inhibited tumor growth by 60.36%.
References
[1] Damaneh MS, et al. A new BET inhibitor, 171, inhibits tumor growth through cell proliferation inhibition more than apoptosis induction. Invest New Drugs. 2020 Jun;38(3):700-713. DOI:10.1007/s10637-019-00818-z
